129 related articles for article (PubMed ID: 21917685)
1. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia.
Koopmans SM; Bot FJ; Lam KH; van Marion AM; de Raeve H; Hebeda KM
Am J Clin Pathol; 2011 Oct; 136(4):618-24. PubMed ID: 21917685
[TBL] [Abstract][Full Text] [Related]
2. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
Brousseau M; Parot-Schinkel E; Moles MP; Boyer F; Hunault M; Rousselet MC
Histopathology; 2010 May; 56(6):758-67. PubMed ID: 20546341
[TBL] [Abstract][Full Text] [Related]
3. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.
Madelung AB; Bondo H; Stamp I; Loevgreen P; Nielsen SL; Falensteen A; Knudsen H; Ehinger M; Dahl-Sørensen R; Mortensen NB; Svendsen KD; Lange T; Ralfkiaer E; Nielsen K; Hasselbalch HC; Thiele J
Am J Hematol; 2013 Dec; 88(12):1012-6. PubMed ID: 23897670
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
Thiele J; Kvasnicka HM; Orazi A
Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
[TBL] [Abstract][Full Text] [Related]
5. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
Campr V
Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
[TBL] [Abstract][Full Text] [Related]
6. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
7. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
[TBL] [Abstract][Full Text] [Related]
8. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
Kvasnicka HM; Thiele J
Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
10. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
11. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
12. Histologic criteria for classification and differential diagnosis of chronic myeloproliferative disorders.
Frisch B; Bartl R; Burkhardt R; Jäger K
Haematologia (Budap); 1984; 17(2):209-26. PubMed ID: 6534829
[TBL] [Abstract][Full Text] [Related]
13. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
15. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
17. [Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases].
Nafe R; Holgado de Colombo S; Choritz H; Georgii A
Pathologe; 1995 Jan; 16(1):34-40. PubMed ID: 7886012
[TBL] [Abstract][Full Text] [Related]
18. Hematopathologic findings in the myeloproliferative disorders.
Dickstein JI; Vardiman JW
Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
20. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
